Key points
- Since 1 August 2022, cannabis for medical purposes has no longer been prohibited in Switzerland. Doctors prescribe it with a narcotics prescription; an exceptional authorisation from the FOPH is no longer required.
- Cannabis for non-medical purposes remains prohibited. Use is punishable by a fine; exceptions apply only to authorised pilot trials.
- Since then, the lists ordinance has classified “cannabis for medical purposes” as a controlled narcotic. The legal threshold is 1.0 per cent total THC.
- Anyone who prescribes cannabis medicines reports the treatment to the FOPH. This data collection is limited until the end of July 2029.
- Hemp and CBD products with less than 1.0 per cent total THC are not subject to the Narcotics Act. However, they can briefly impair fitness to drive.
Medical cannabis has been legal in Switzerland since 1 August 2022. On that day, an amendment to the Narcotics Act (BetmG) came into force that lifted the ban on cannabis for medical purposes. Since then, doctors have prescribed cannabis medicines on their own responsibility with a narcotics prescription, without an exceptional authorisation from the Federal Office of Public Health (FOPH).1,3,4
Nothing has changed for cannabis for non-medical purposes: it remains prohibited. Hemp with less than 1.0 per cent total THC, such as CBD products, is permitted, however, because it does not fall under the Narcotics Act. This article sets out the three areas: medical, non-medical and CBD.1,4,5
Cannabis legal in Switzerland: what changed on 1 August 2022
Parliament adopted the amendment to the Narcotics Act on 19 March 2021. The Federal Council brought it into force, together with amended ordinances, on 1 August 2022.1,3
The core of the revision is a single sentence in the law. Article 8 BetmG prohibits the cultivation, import, manufacture and placing on the market of certain narcotics. Since 2022, it mentions cannabis only “insofar as it is not used for medical purposes”. Previously, cannabis was prohibited in general, and medical use was only possible with an exceptional authorisation from the FOPH.2,3
According to the FOPH, the office granted around 15,000 such exceptional authorisations from 2012 to 2019, and the majority of applications were approved. In the FOPH’s view, this no longer matched the exceptional character of the law and caused a heavy workload for doctors and the authority.4
1 August 2022
No more FOPH exceptional authorisation: what this means for patients
Since August 2022, treatment with cannabis medicines no longer requires an exceptional authorisation from the FOPH. According to the FOPH, responsibility for the treatment lies solely with the doctors.1
For you, this means: to obtain a cannabis medicine at the pharmacy, all you need is a narcotics prescription from your treating doctor.4 Whether treatment is an option for you is decided by the doctor after a medical assessment. There is no entitlement to a prescription.
According to the FOPH, the change affects all unauthorised THC-containing medicines that a pharmacy prepares for a specific person on a doctor’s prescription (magistral preparation), as well as authorised ready-made medicines prescribed outside the authorised indication or dosage form. For Sativex, which Swissmedic has authorised as an add-on therapy for moderate to severe spasticity in multiple sclerosis, nothing changes when it is used in accordance with its authorisation. It was already legal before.4
Since 2022, the cultivation, processing, manufacture and trade of medical cannabis have been subject to the Swissmedic authorisation and control system, like other narcotics used in medicine, such as methadone or morphine. Commercial export is now also permitted, with Swissmedic authorisation.1
The list in the BetmVV-EDI: “cannabis for medical purposes”
Which substances are controlled as narcotics is set out in lists by the Narcotics Lists Ordinance of the Federal Department of Home Affairs (BetmVV-EDI). The FDHA amended it on 22 June 2022, likewise with entry into force on 1 August 2022.5,6
Since then, there have been two entries side by side:
- “Cannabis for medical purposes” in list a, the list of controlled narcotics that may be placed on the market. This covers hemp plants, parts of them and preparations for medical purposes and pharmaceutical production with a total THC content of at least 1.0 per cent.
- “Cannabis” in list d, the list of prohibited narcotics. This concerns the same plants and preparations when they are not used medically.5
The threshold of 1.0 per cent total THC applies in both entries. Below it, hemp does not fall under narcotics law. Since the change, the FOPH has described medical cannabis as a controlled narcotic that may be placed on the market to a limited extent.4,5
Classification in list a has practical consequences, for example for travel: the rules for sick travellers apply to narcotics in this list, including the Schengen certificate. More on this in the article Schengen certificate for narcotics.
Data collection under Art. 8b BetmG: what your doctor reports
The revision added a new Article 8b to the Narcotics Act. The FOPH collects data on medical treatments with cannabis medicines that are not authorised or are prescribed outside their authorisation. The data serve the scientific evaluation of the revision and statistical analysis. The article applies for a limited period from 1 August 2022 to 31 July 2029.2
In practice, the prescribing doctor records the treatment in the MeCanna reporting system. According to the FOPH, the reports include sociodemographic information, indication, preparation and dosage, concomitant medication and observed effects and side effects. Reports are made at the first prescription, after one and after two years and if the therapy is discontinued.4
According to the FOPH, the data are stored in coded form and can only be viewed in full by the treating doctor. Research institutions receive them on request only in anonymised form. According to the FOPH, data collection was a political precondition for lifting the ban.4
Recreational use remains prohibited
Cannabis for non-medical purposes remains prohibited in Switzerland.1 Anyone who uses narcotics without authorisation is punished with a fine. In minor cases, the proceedings may be dropped or a warning issued.2
According to the law, anyone who merely prepares a minor quantity for their own use is not liable to prosecution. 10 grams of cannabis count as a minor quantity. This is not permission to use: use itself remains punishable under Article 19a.2
The scientific pilot trials under Article 8a BetmG are a separate exception. The FOPH may authorise trials limited in place, time and subject matter that examine the effects of new rules on non-medical cannabis use. This provision is limited until 14 May 2031 and has nothing to do with medical cannabis.2
CBD and hemp under 1 per cent THC: legal, but not without rules
Hemp and hemp products with a total THC content below 1.0 per cent are not subject to the Narcotics Act. The FOPH expressly states that medicines with cannabidiol (CBD) as the main active ingredient and less than 1 per cent total THC do not fall under it either.4,5
That does not mean these products are free of rules. Which law applies depends on what a product is sold as: as a smoking product under tobacco products law, as food, a cosmetic, a chemical or a therapeutic product. The federal authorities describe this in a joint enforcement guide.7
Two points from this enforcement guide directly affect everyday life. Hemp products with a low THC content can briefly impair fitness to drive. And abroad, stricter regulations and different THC limits mean there is a risk of criminal prosecution.7 In road traffic, zero tolerance applies to THC without a medical prescription, regardless of whether the THC comes from a legal CBD product.8
What the change in the law did not change
Three things have stayed the same, even though this is often understood differently:
- Costs: The revision did not change the requirements for reimbursement. According to the FOPH, basic health insurance covers cannabis medicines only in exceptional cases, as part of individual-case reimbursement and after a cost approval from the health insurer. A supplementary insurance may possibly be liable to pay.1,4
- Road traffic: A prescription is not a permit to drive. It only changes the fact that THC in the blood alone no longer counts as proof of unfitness to drive if you can prove the prescription. Details in the article Driving with a prescription.8
- Passing on: A cannabis medicine is intended for the person to whom it was prescribed. Anyone who supplies narcotics without authorisation is acting outside the medical exception of the law.2
How it works at evidena
At evidena, the doctor decides in a video consultation whether treatment with cannabis medicines is a medical option. A prescription is only issued if the medical assessment supports it. If a prescription is issued, it must be filled at the pharmacy within one month. As a rule, the prescribed quantity covers one month, in justified cases at most three months of treatment.9 You can book appointments at portal.evidena.care. We answer questions via WhatsApp or at info@evidena.care. The process is described under How it works, the costs under Costs.
Conclusion
Since 1 August 2022, medical cannabis in Switzerland has been a controlled narcotic like morphine: prescribed with a narcotics prescription, without FOPH authorisation, with a report to the FOPH. Cannabis for non-medical purposes remains prohibited. CBD products below 1.0 per cent total THC do not fall under the Narcotics Act, but can still have consequences in road traffic and abroad. Terms are explained in the glossary.
Frequently asked questions
Is cannabis legal in Switzerland?
For medical purposes, yes, if a doctor prescribes it and a pharmacy dispenses it. For non-medical purposes, cannabis with 1.0 per cent total THC or more remains prohibited.
Do I still need an FOPH authorisation?
No. Since 1 August 2022, treatment no longer requires an exceptional authorisation from the FOPH. A narcotics prescription is sufficient.
Will my data be reported to the FOPH?
Your doctor reports the treatment to the FOPH. According to the FOPH, the data are stored in coded form and can only be viewed in full by the treating doctor.
Is CBD legal in Switzerland?
Products with less than 1.0 per cent total THC are not subject to the Narcotics Act. Which other rules apply depends on what the product is sold as, for example a smoking product, food or medicine.
Has the health insurer paid for cannabis medicines since 2022?
The change in the law did not change reimbursement. According to the FOPH, basic health insurance covers cannabis medicines only in exceptional cases, after a cost approval.
Sources
- Gesetzesänderung Cannabisarzneimittel, Bundesamt für Gesundheit BAG (accessed 13 November 2026)
- Bundesgesetz über die Betäubungsmittel und die psychotropen Stoffe (BetmG), SR 812.121, Art. 8 Abs. 1 Bst. d und Abs. 5, Art. 8a, Art. 8b, Art. 19a, Art. 19b, Fedlex (accessed 13 November 2026)
- Änderung vom 19. März 2021 des Betäubungsmittelgesetzes (Cannabisarzneimittel), AS 2022 385, Fedlex (accessed 13 November 2026)
- FAQ Cannabisarzneimittel, Bundesamt für Gesundheit BAG, veröffentlicht am 4. März 2025 (accessed 13 November 2026)
- Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (BetmVV-EDI), SR 812.121.11, Art. 2 und Anhänge 1 und 5, Fedlex (accessed 13 November 2026)
- Änderung vom 22. Juni 2022 der Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), AS 2022 387, Fedlex (accessed 13 November 2026)
- Produkte mit Cannabidiol (CBD) und anderen Cannabinoiden, die nicht dem Betäubungsmittelrecht unterliegen: Überblick und Vollzugshilfe, Fachgremium für Abgrenzungsfragen (Swissmedic, BAG, BLV, KAV, VKCS), Version 8.0, gültig ab 1. Mai 2025, Kapitel 5.8 (accessed 13 November 2026)
- Verkehrsregelnverordnung (VRV), SR 741.11, Art. 2 Abs. 2 und 2ter, Fedlex (accessed 13 November 2026)
- Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, Art. 46 und 47, Stand am 23. Januar 2023, Fedlex (accessed 13 November 2026)